A letter that the Scottish Parliament felt unable to publish

With careful thought, and backed with full supporting evidence,  I sent the following letter of the 2nd February 2016 to support my petition for a Sunshine Act for Scotland. The Senior Clerk … Continue reading A letter that the Scottish Parliament felt unable to publish

“A robust learning environment for healthcare professionals”

I have recently posted on the promotion of Lurasidone (Latuda) in the UK. This has raised concerns for me about transparency of conflicts of interest for some of the key … Continue reading “A robust learning environment for healthcare professionals”

Lurasidone – financial conflicts of interest

The launch in the UK of Lurisidone began in August 2014. My previous post on Lurasidone (Latuda) which has now been marketed in the UK followed the financial interests of … Continue reading Lurasidone – financial conflicts of interest

Stephen Stahl: $3,581,159 in payments from Pharma

In my last post I considered the level of transparency provided by the British Association for Psychopharmacology (BAP) in relation to its recently published Guidelines on prescribing for depressive disorders. … Continue reading Stephen Stahl: $3,581,159 in payments from Pharma